Search results
Results From The WOW.Com Content Network
Synthetic cannabinoids were made for cannabinoid research focusing on tetrahydrocannabinol (THC), cannabinoid receptors, and the endocannabinoids that activate them in the body. Synthetic cannabinoids were needed partly due to legal restrictions on natural cannabinoids, which make them difficult to obtain for research.
JWH-018 is a full agonist of both the CB 1 and CB 2 cannabinoid receptors, with a reported binding affinity of 9.00 ± 5.00 nM at CB 1 and 2.94 ± 2.65 nM at CB 2. [6] JWH-018 has an EC 50 of 102 nM for human CB 1 receptors, and 133 nM for human CB 2 receptors. [16]
Hexahydrocannabiphorol (HHCP, sometimes mistakenly referred to as hexahydroxycannabiphorol) is a semi-synthetic cannabinoid derivative which has been marketed since around 2021. [1] [2] It is believed to be made from the hydrogenation of tetrahydrocannabiphorol (THCP). THCP is only reported as a trace component of cannabis in 2019. [3]
Cannabinoids, including tetrahydrocannabinol (THC), the active drug in cannabis, can also be produced by bioengineered yeast, a process colloquially known as pharming. [1] In 2007, a research group reported the successful transgenic placement of a THCA synthase gene from Cannabis plant into the Pichia pastoris yeast, giving the yeast the ability to turn the precursor molecule cannabigerolic ...
HHC-acetate (Hexahydrocannabinol-O-acetate, HHC-O) is a semi-synthetic cannabinoid derivative which has been marketed since around 2022. [1] [2] It is believed to be made in a three step process from cannabidiol extracted from hemp. [3]
Cannabinoids and their K i values [a] Name Class K i / nM at CB 1 K i / nM at CB 2 Selectivity Structure JWH-004: Naphthoylindole: 48 ± 13: 4 ± 1.5: CB 2 (12x) JWH ...
Synthetic biology, or breaking down life into its basic component parts to create enhanced biological systems, can be likened to writing software that enables life. Or genetic engineering on steroids.
In a 2023 study, anecdotal claims surrounding THC-O-acetate's supposed ability to initiate psychedelic experiences were shown to not be significant. Answers using the Mystical Experience Questionnaire (MEQ) were under the threshold of a true experience, and those who had used classical psychedelics such as LSD or psilocybin consistently scored lower on the MEQ.